Key result
Magmaris scaffold in bifurcation lesions triggers fractures and embolization in ~27% of cases.
Why the study?
Polymer-based bioresorbable scaffolds have low radial strength and expansion capacity limiting their use in coronary bifurcation lesions, and magnesium-based BRS may offer improved mechanical properties.
Does a sirolimus-eluting magnesium-based bioresorbable scaffold improve clinical safety and healing in patients with simple coronary bifurcation lesions?
Does a sirolimus-eluting magnesium-based bioresorbable scaffold improve clinical safety and healing in patients with simple coronary bifurcation lesions?
Implanting a magnesium bioresorbable scaffold using the provisional technique in simple bifurcation lesions is associated with an unacceptable rate of scaffold fracture and embolization.
Scaffold fractures advise caution with Magmaris in bifurcations; leaves open magnesium scaffold suitability for complex lesions.
OBJECTIVES: To evaluate the feasibility, safety, and healing response of a magnesium-based bioresorbable scaffold (BRS) in the treatment of simple bifurcation lesions using the single stent provisional technique. BACKGROUND: BRS may hold potential advantages in the treatment of coronary bifurcation lesions, however low radial strength and expansion capacity has been an issue with polymer-based scaffolds. The magnesium BRS may prove suitable for bifurcation treatment as its mechanical properties are closer to those of permanent metallic drug-eluting stents. METHODS: The study was a proof-of-concept study with planned inclusion of 20 patients with stable angina pectoris and a bifurcation lesion involving a large side branch (SB) > 2.5 mm with less than 50% diameter stenosis. Procedure and healing response were evaluated by optical coherence tomography (OCT). The main endpoints were a composite clinical safety endpoint and an OCT healing index at 1 month (range: 0-98). RESULTS: Eleven patients were included in the study. The study was prematurely terminated due to scaffold fractures and embolization of scaffold fragments in three cases requiring bailout stenting with drug-eluting stents. One patient underwent bypass surgery at 3 months due to stenosis proximal to the study segment. All SB were patent for 1 month. One-month OCT evaluation showed strut coverage of 96.9% and no malapposition. Scaffold fractures and uncovered jailing struts resulted in a less favorable mean OCT healing index score of 10.4 ± 9.0. CONCLUSIONS: Implanting a magnesium scaffold by the provisional technique in nontrue bifurcation lesions was associated with scaffold fracture, embolization of scaffold fragments, and a high need for bailout stenting.
No takes yet. Share an insight, caveat, or question.
Barkholt et al. (2021) studied Coronary bifurcation lesions (n=11). Magmaris bioresorbable scaffold was evaluated on Clinical safety at 1 month (procedural MI, nonprocedural MI, restenosis causing ischemia, or cardiac death). Implantation of the Magmaris magnesium bioresorbable scaffold in simple coronary bifurcation lesions resulted in scaffold fractures and embolization in 3 of 11 cases, prompting premature study termination.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: